BeiGene

百济神州

At BeiGene, the power of change propels BeiGene forward. BeiGene has introduced a new global strategic theme, “Change Is The Cure™”, which will guide BeiGene in five key areas, including advancing global health, empowering employees, sustainable innovation, supporting the community, and responsible operation. In each key area, BeiGene has identified two strategic imperatives, around which BeiGene will set specific goals and report progress.

The theme “Change Is The Cure” reflects BeiGene’s industry vision that goes beyond product thinking and paves the way for a better world. BeiGene promotes change by:

Committing to making life-saving drugs accessible to more patients worldwide.

Challenging the status quo, breaking boundaries, and turning the impossible into possible.

Eliminating systemic injustice and inequality.

Creating unlimited opportunities for everyone and helping them grow.

Breaking conventions.

Making cutting-edge innovative drugs affordable for more people worldwide:

BeiGene believes that everyone, no matter where they are, has the right to access innovative drugs that can change their lives. From discovering new therapies to scaling up commercialization, BeiGene is working to close the health equity gap by expanding the accessibility of BeiGene products to global patients. BeiGene’s vision is to be a game-changer in the biotech industry, offering effective, accessible, and affordable medications for cancer patients worldwide. To this end, BeiGene has carved a unique path within the industry.

With a broad product pipeline, including many pre-clinical candidate drugs with the potential to be “first-in-class” or “best-in-class”, BeiGene is developing these drugs to provide patients with new innovative treatments.

BeiGene’s new global clinical development model has established independent clinical development capabilities, achieving “de-CROization.” BeiGene conducts clinical trials in multiple countries and regions, recruiting patients faster and reducing clinical trial time and costs by one-third.

BeiGene’s commercialization model aims to cover not only developed markets but also markets in developing regions. Pricing is determined based on expanding patient accessibility.

A robust safety and quality system supports operations, ensuring product quality to protect patient safety and health, and provides transparent information to stakeholders.

At BeiGene, it’s hoped that patients everywhere can access affordable innovative drugs. To get life-saving innovative treatments to more patients faster, BeiGene conducts clinical trials globally, developing high-quality drugs faster than typical clinical trials.

To date, BeiGene has 90 ongoing or planned clinical trials, including 30+ pivotal or potential registration trials in 45+ regions, such as China, Brazil, Poland, Mexico, and Turkey, which are not typically early targets for innovative oncology candidate drug clinical trials.

BeiGene can further expand the accessibility of life-saving treatments by seeking like-minded partners. Utilizing BeiGene’s research, development, and commercial assets, or partnering to bring BeiGene’s therapies to new regions, maximizes partnerships to achieve BeiGene’s mission, getting more people the essential drugs they need.

Centered on patients, BeiGene is committed to providing comprehensive support for patients and their caregivers.

BeiGene always maintains a commitment to safety, compliance, and quality in its products, research, and services.

BeiGene aims to deliver high-quality drugs that meet or exceed patient and regulatory expectations.

BeiGene hopes every employee and partner will join them in finding opportunities to elevate BeiGene’s performance in product quality.

Good Clinical Practice (GCP) is the commonly used ethical and scientific quality standard for conducting human clinical trials. This quality standard runs through every link of clinical development, allowing BeiGene to learn and gain experience throughout the clinical trial process.

BeiGene’s manufacturing bases are built to GMP design standards set by the FDA, NMPA, and EMA, using cutting-edge technology, helping BeiGene operate efficiently while responsibly using resources.

Since its inception, BeiGene’s R&D team has been dedicated to advancing candidate drugs and product pipelines with the potential to be “first-in-class” or “best-in-class”. For this, BeiGene has established one of the world’s largest oncology research teams. BeiGene’s global clinical development team is conducting extensive clinical trial programs worldwide. The many clinical trial outcomes, drug approvals, and commercial collaborations BeiGene has achieved fully demonstrate the company’s R&D strength and quality standards.

Globally, countless cancer patients face tremendous challenges daily, with many treatment needs unmet. Some patients search tirelessly for a remedy, while others have potential treatment options but cannot afford the high costs.

Facing these challenges, BeiGene is intensively advancing its research on innovative, high-quality candidate drugs and product combinations, focusing on hematological and solid tumors, and aiming to bring more high-quality innovative drugs with “first-in-class” or “best-in-class” potential to patients.

Offering high-quality innovative drugs that are accessible and affordable to cancer patients worldwide is BeiGene’s unwavering commitment.

Innovative pathways, leveraging biology and scalability:
BeiGene’s research methods in cancer biology combine cutting-edge drug development modes and processes with the scalable capabilities of a global organization. Oncology immunology, the cornerstone of cancer treatment, is a major focus for BeiGene. BeiGene believes that combination therapies in the immuno-oncology field, as well as the combination of immunotherapy with other treatments, have significant therapeutic potential.

Based on scientific drug design to tackle cancer:
BeiGene has established a host of novel in vitro, ex vivo, and in vivo cancer models to better select targets and screen and evaluate drug molecules for use in mono or combination therapies. Discovering engine factors in tumor-immune system interactions and primary tumor biopsies is essential for developing BeiGene’s new cancer models. Additionally, BeiGene’s cancer models integrate elements.